Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac

References

• LinebargerEJHardtenDRShahGKPhacoemulsification and modern cataract surgerySurv Ophthalmol19994412314710541151
   PubMed Web of Science ®Google Scholar
• GogatePMKulkarniSRKrishnaiahSSafety and efficacy of phacoemulsification compared with manual small-incision cataract surgery by a randomized controlled clinical trial: six-week resultsOphthalmology200511286987415878068
   PubMed Web of Science ®Google Scholar
• RiazYMehtaJSWormaldRSurgical interventions for age-related cataractCochrane Database Syst Rev20064CD00132317054134
   PubMed Web of Science ®Google Scholar
• MohammadpourMJafarinasabMRJavadiMAOutcomes of acute postoperative inflammation after cataract surgeryEur J Ophthalmol200717202817294379
   PubMed Web of Science ®Google Scholar
• PodosSMProstaglandins, nonsteroidal anti-inflammatory agents and eye diseaseTrans Am Ophthalmol Soc197674637660194383
   PubMedGoogle Scholar
• El-HaraziSMRuizRSFeldmanRMA randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cellsOphthalmic Surg Laser199829539544
   PubMedGoogle Scholar
• FlachAJDolanBJDonahueMEComparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgeryOphthalmology1998105177517799754191
   PubMed Web of Science ®Google Scholar
• El-HaraziSMRuizRSFeldmanRMEfficacy of preoperative versus postoperative ketorolac tromethamine 0.5% in reducing inflammation after cataract surgeryJ Cataract Refract Surg2000261626163011084270
   PubMed Web of Science ®Google Scholar
• SolomonKDCheethamJKDeGryseRTopical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgeryOphthalmology2001a10833133711158809
   PubMed Web of Science ®Google Scholar
• SolomonKDVromanDTBarkerDComparison of ketorolac tromethamine 0.5% and rimexolone 1% to control inflammation after cataract extraction. Prospective randomized double-masked studyJ Cataract Refract Surg2001b271232123711524195
   PubMed Web of Science ®Google Scholar
• FlachAJTopical nonsteroidal antiinflammatory drugs in ophthalmologyInt Ophthalmol Clin20024211112189605
   PubMedGoogle Scholar
• HirneissCNeubauerASKampikAComparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction: a prospective, randomized, double-masked studyGraefes Arch Clin Exp Ophthalmol200524376877315756571
   PubMed Web of Science ®Google Scholar
• DonnenfeldEDPerryHDWittpennJRPreoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curveJ Cataract Refract Surg2006321474148216931258
   PubMed Web of Science ®Google Scholar
• HeierJSToppingTMBaumannSKetorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edemaOphthalmology20001072034203811054327
   PubMed Web of Science ®Google Scholar
• MuhtasebMKalhoroAIonidesAA system for preoperative stratification of cataract patients according to risk of intraoperative complications: a prospective analysis of 1441 casesBr J Ophthalmol2004881242124615377542
   PubMed Web of Science ®Google Scholar
• SolomonKDTurkaljJWWhitesideSBTopical 0.5% ketorolac vs 0.03% flurbiprofen for inhibition of miosis during cataract surgeryArch Ophthalmol1997115111911229298051
   PubMed Web of Science ®Google Scholar
• ThallerVTKulshresthaMKBellKThe effect of pre-operative topical flurbiprofen or diclofenac on pupil dilatationEye20001464264511040914
   PubMed Web of Science ®Google Scholar
• SnyderRWSiekertRWSchwiegerlingJAcular as a single agent for use as an antimiotic and anti-inflammatory in cataract surgeryJ Cataract Refract Surg2000261225122711008052
   PubMed Web of Science ®Google Scholar
• SrinivasanRMadhavarangaTopical ketorolac tromethamine 0.5% versus diclofenac sodium 0.1% to inhibit miosis during cataract surgeryJ Cataract Refract Surg20022851752011973101
   PubMed Web of Science ®Google Scholar
• ShaikhMYMarsJSHeavenCJPrednisolone and flurbiprofen drops to maintain mydriasis during phacoemulsification cataract surgeryJ Cataract Refract Surg2003292372237714709299
   PubMed Web of Science ®Google Scholar
• FlachAJThe incidence, pathogenesis and treatment of cystoid macular edema following cataract surgeryTrans Am Ophthalmol Soc19989655763410360304
   PubMedGoogle Scholar
• MiyakeKIbarakiNProstaglandins and cystoid macular edemaSurv Ophthalmol200247Suppl 1S203S21812204717
   PubMed Web of Science ®Google Scholar
• UrsellPGSpaltonDJWhitcupSMCystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuityJ Cataract Refract Surg1999251492149710569164
   PubMed Web of Science ®Google Scholar
• MentesJErakgunTAfrashiFIncidence of cystoid macular edema after uncomplicated phacoemulsificationOphthalmologica200321740841214573973
   PubMed Web of Science ®Google Scholar
• RhoDSTreatment of acute pseudophakic cystoid macular edema: Diclofenac versus ketorolacJ Cataract Refract Surg2003292378238414709300
   PubMed Web of Science ®Google Scholar
• YavasGFOzturkFKusbeciTPreoperative topical indomethacin to prevent pseudophakic cystoid macular edemaJ Cataract Refract Surg20073380480717466852
   PubMed Web of Science ®Google Scholar
• LaneSSModiSSLehmannRPNepafenac suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgeryJ Cataract Refract Surg200733535817189793
   PubMed Web of Science ®Google Scholar
• LaneSSNepafenac: a unique nonsteroidal prodrugInt Ophthalmol Clin200646132017060788
   PubMedGoogle Scholar
• WaltersTRaizmanMErnestPIn vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenacJ Cataract Refract Surg2007331539154517720067
   PubMed Web of Science ®Google Scholar
• KeTLGraffGSpellmanJMNepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriersInflammation20002437138410850858
   PubMed Web of Science ®Google Scholar
• LindstromRKimTOcular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenacCurr Med Res Opin20062239740416466612
   PubMed Web of Science ®Google Scholar
• JabsDANussenblattRBRosenbaumJTStandardization of Uveitis Nomenclature (SUN) Working GroupStandardization of uveitis nomenclature for reporting clinical data. Results of the First International WorkshopAm J Ophthalmol200514050951616196117
   PubMed Web of Science ®Google Scholar
• AlmeidaDRJohnsonDHollandsHEffect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgeryJ Cataract Refract Surg200834646918165083
   PubMed Web of Science ®Google Scholar
• OzdemirHKaracorluSKaracorluMPostoperative subretinal fluid associated with cystoid macular edema following cataract surgeryRetina20052522322515689820
   PubMed Web of Science ®Google Scholar
• LoboCLFariaPMSoaresMAMacular alterations after small-incision cataract surgeryJ Cataract Refract Surg20043075276015093635
   PubMed Web of Science ®Google Scholar
• WolfEJBraunsteinAShihCIncidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenacJ Cataract Refract Surg2007331546154917720068
   PubMed Web of Science ®Google Scholar
• HariprasadSMCallananDGaineySCystoid and diabetic macular edema treated with nepafenac 0.1%J Ocul Pharmacol Ther200723285288
   Web of Science ®Google Scholar
• CallananDWilliamsPTopical nepafenac in the treatment of diabetic macular edemaClin OphthalmolIn press
   Google Scholar
• WarrenKAFoxJETopical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patientsRetina2008281427143418664937
   PubMed Web of Science ®Google Scholar